About Medeor Therapeutics



MAKING THE DREAM OF TRANSPLANT IMMUNE TOLERANCE A REALITY


MEDEOR THERAPEUTICS is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients. Our team of professionals possesses deep expertise in hematology, cellular immunotherapy, and transplantation product development. Medeor's series of product candidates each comprise a unique composition of different types of hematopoietic organ donor-derived cells, based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient, to achieve donor-specific immune tolerance, to prevent transplant organ loss, to reduce or eliminate chronic immunosuppressive drug therapy, and thereby to improve patient outcomes. Our pipeline addresses critical medical needs of the approximately 130,000 annual organ transplant recipients worldwide, including greater than 30,000 annual transplant recipients in the US alone. Medeor is headquartered in San Mateo, California.


Learn About The Holy Grail

Senior Management



Dr. Deitcher is an innovative business leader who has more than 25 years of life science product development experience including cellular therapeutics, biologics, small molecules, and diagnostics. He was President, CEO and Board Member at Talon Therapeutics, a specialty biopharmaceutical company focused on novel cancer drug delivery...
Read More

Steven R. Deitcher, M.D.

Founder, President, CEO, and Board Member
Dr. Weber joined Medeor Therapeutics in 2016 to lead all global regulatory and quality efforts related to MDR-101. He has more than 20 years of regulatory affairs experience with biological products. Previously, he was Executive Vice President of Global Regulatory Affairs and Quality Management for Mesoblast LTD. Prior to joining Mesoblast...
Read More

Darin J. Weber, Ph.D.

Senior Vice President, Regulatory Affairs & Quality
Dr. Read joined Medeor Therapeutics in 2015 to lead MDR-101 product development efforts ranging from donor stem cell collection to commercial manufacturing and final product delivery to patients. She has more than 20 years of product development experience with biological products. Previously, Dr. Read held cell therapy ...
Read More

Elizabeth "EJ" Read, M.D.

Senior Vice President, Product Development
Dr. Batty joined Medeor Therapeutics in 2016 as Chief Medical Officer to lead the clinical development and medical affairs efforts related to Medeor's organ transplantation programs. Previously, Scott held an executive management role at ImmunArray as well as leadership roles in transplant and stem cell product clinical development ...
Read More

D. Scott Batty, Jr., M.D

Chief Medical Officer
Matthew J. Plunkett assumed his role as our Chief Financial and Business Officer in September 2017. He is responsible for all finance and corporate development functions at the Company...
Read More

Matthew Plunkett, PH.D

Chief Financial & Business Officer





Learn More About Our Board Members